Thursday, June 30, 2022


Category: Clinical Trial and Studies

Avacta Announces 2nd Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

AVA6000 is a novel form of doxorubicin that has been modified with Avacta’s pre|CISION™ FAP-activated delivery platform to improve its safety and therapeutic index. AVA6000 has been designed to limit cell penetration of the drug, and therefore its cell killing effect, until it is specifically activated by fibroblast activation protein a (FAP) which is in high concentration in many solid tumours compared with healthy tissues.

Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

The DiSCOVER trial is a prospective, Phase 3, randomized, double-blind, placebo-controlled efficacy trial designed to evaluate EDSIVO™ (celiprolol) in patients with genetically confirmed COL3A1-positive vEDS using a decentralized clinical trial design and an independent adjudication committee.

Mountain Valley MD Successfully Completes Pre-Clinical Pharmacokinetic Study For Soluvec™1%

“The data generated for IM and SC administration is very encouraging in our goal to achieve effective plasma concentrations with Soluvec™ compared to oral ivermectin, while also raising some interesting questions about the potential for dose reductions to achieve efficacy and safety outcomes in future applications,” commented Dr. Azhar Rana, Chief Medical Officer of MVMD.

Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole

Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo.

Teva Pharmaceuticals Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)

Teva Pharmaceuticals reports interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment.

Timber Pharmaceuticals Announces First Patients Enrolled in Phase 3 ASCEND Clinical Trial Evaluating TMB-001 in Congenital Ichthyosis

ASCEND will evaluate the efficacy, pharmacokinetics and safety of TMB-001 0.05%, a topical isotretinoin formulated using Timber Pharmaceuticals patented IPEG™ delivery system, for the treatment of moderate to severe forms of congenital ichthyosis